JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DiSesa, V. J.
Right arrow Articles by Cohn, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DiSesa, V. J.
Right arrow Articles by Cohn, L. H.

The Journal of Thoracic and Cardiovascular Surgery, Vol 94, 220-224, Copyright © 1987 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Performance of a fabricated trileaflet porcine bioprosthesis. Midterm follow-up of the Hancock modified-orifice valve

VJ DiSesa, EN Allred, W Kowalker, RJ Shemin, JJ Collins Jr and LH Cohn

The fabrication of the Hancock modified-orifice valve raised questions about its long-term durability. Since 1976, 315 patients (206 male, 109 female) with a mean age of 63 years underwent aortic valve replacement with 21 mm (n = 120), 23 mm (n = 153), 25 mm (n = 36), and 27 mm (n = 6) Hancock modified-orifice valves. There were five operative deaths (1.6% mortality). Two hundred sixty-two patients are alive 2 to 117 (mean 53) months postoperatively. Actuarial probability of survival at 96 months was 78% +/- 3%. Two hundred twenty-two survivors are in Functional Class I or II. Forty-three patients have had valve-related complications: thromboembolism in 25 (1.9%/pt-yr), primary valve dysfunction in eight (0.6%/pt-yr), and endocarditis in 11 (0.8%/pt-yr). Twelve patients have required reoperation (0.8%/pt-yr) for primary valve dysfunction (four patients), for endocarditis (five patients), and for perivalvular leak (three patients). At 96 months the actuarial probability of freedom from thromboembolism was 87% +/- 3%, from primary valve dysfunction 97% +/- 2%, and from endocarditis 92% +/- 3%. The probability of freedom from all valve-related complications was 78% +/- 4% and from reoperation 94% +/- 2%. The performance of this prosthesis justifies its continued use for aortic valve replacement.


This article has been cited by other articles:


Home page
 NEJMHome page
K. E. Hammermeister, G. K. Sethi, W. G. Henderson, C. Oprian, T. Kim, S. Rahimtoola, and The Veterans Affairs Cooperative Study on Valvular
A Comparison of Outcomes in Men 11 Years after Heart-Valve Replacement with a Mechanical Valve or Bioprosthesis
N. Engl. J. Med., May 6, 1993; 328(18): 1289 - 1296.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1987 by The American Association for Thoracic Surgery.